Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

“…Peripheral lymphocyte count may be a biomarker of nivolumab treatment efficacy against unresectable or recurrent GC. 21 Differentiated histological type was another factor independently associated with good survival. The direct relationship between histological type and efficacy of nivolumab treatment remains unclear; however, programmed cell death ligand 1 (PD-L1) expression may account for this suspected link.…”

Association between peripheral eosinophils and clinical outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitors

“…Considering the difficulties in methodology and interpretation with PD-L1 immunostaining, other predictive factors have been sought. In recent years, there have been reports that peripheral blood leukocytes may be a promising predictor in ICPI therapy [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19].…”

Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective

“…A study on the profile of T lymphocytes in the peripheral blood of NSCLC patients before or just starting anti-PD-1/PD-L1 therapy reports a positive association between high PD1+CD4+/total CD4+ T cell ratio and long PFS. [ 81 ] Furthermore, high ratio of CD4+ and CD8+ central memory T cell to effector T cell in the blood is positively associated with high PD-L1 expression levels and PFS of NSCLC patients receiving nivolumab. [ 82 ] Additionally, analysis of blood-based subtypes of immune cells among atezolizumab-treated advanced NSCLC patients revealed a reduction of regulatory T cells and MDSCs in the disease-controlled patients.…”